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Abstract
Background: The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients
currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or
have undergone an intralesional resection of the primary tumor. After irradiation-induced DNA damage, OS cells
sustain a prolonged G2 cell cycle checkpoint arrest allowing DNA repair and evasion of cell death. Inhibition of
WEE1 kinase leads to abrogation of the G2 arrest and could sensitize OS cells to irradiation induced cell death.
Methods: WEE1 expression in OS was investigated by gene-expression data analysis and immunohistochemistry of
tumor samples. WEE1 expression in OS cell lines and human osteoblasts was investigated by Western blot. The
effect of WEE1 inhibition on the radiosensitivity of OS cells was assessed by cell viability and caspase activation
analyses after combination treatment. The presence of DNA damage was visualized using immunofluorescence
microscopy. Cell cycle effects were investigated by flow cytometry and WEE1 kinase regulation was analyzed by
Western blot.
Results: WEE1 expression is found in the majority of tested OS tissue samples. Small molecule drug PD0166285
inhibits WEE1 kinase activity. In the presence of WEE1-inhibitor, irradiated cells fail to repair their damaged DNA,
and show higher levels of caspase activation. The inhibition of WEE1 effectively abrogates the irradiation-induced
G2 arrest in OS cells, forcing the cells into premature, catastrophic mitosis, thus enhancing cell death after
irradiation treatment.
Conclusion: We show that PD0166285, a small molecule WEE1 kinase inhibitor, can abrogate the G2 checkpoint in
OS cells, pushing them into mitotic catastrophe and thus sensitizing OS cells to irradiation-induced cell death. This
suggests that WEE1 inhibition may be a promising strategy to enhance the radiotherapy effect in patients with OS.
Background
Osteosarcoma (OS) is the most common primary malig-
nant bone tumor in children and adolescents. The gold
standard for treatment of OS consists of multi-agent
neoadjuvant chemotherapy, radical excision of the
tumor and adjuvant chemotherapy [1-3]. With this
treatment regimen, 5-year survival rates of approxi-
mately 65% are obtained in localized disease. In patients
with axial and/or inoperable OS, local control is difficult
to achieve and there is a high risk of relapse and/or
metastasis. The prognosis for these patients is worse
with a 5-year survival of around 25% [4-7]. Clearly,
alternative treatment options for OS are warranted for
patients in whom local control can be scarcely achieved
and therefore have a high risk of recurrence. Radiother-
apy as a treatment modality for cancer has evolved over
the past decades, but its use in OS treatment is contro-
versial because OS is considered to be a relatively radio-
resistant tumor [2,3,5,7]. At present, radiotherapy is
applied only in a select group of patients with OS,
namely those who suffer from inoperable (advanced
extremity, axial or head-and-neck) OS, patients with
painful bone metastases and patients who refuse surgery.
Radiotherapy can give local control in OS when applied
as an adjuvant therapy in patients who have undergone
an intralesional resection of the primary tumor with
subsequent irradiation of the surgical margins
[1-3,5,8-11]. Technical progression in the field of
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radiotherapy has facilitated a more precise localised
delivery of radiation and thus warranted dose-intensifi-
cation at the site of the tumor. This is of value since the
high irradiation doses needed for tumor control are dif-
ficult to achieve in patients with tumors that lie in the
proximity of delicate structures, as is often the case in
axial OS. Regularly, adverse side effects limit the dose
that can be applied. Although still considered an
advanced technique, the use of proton radiotherapy can
be even more exactly localized to deliver a higher irra-
diation dose in the tumor while sparing adjacent healthy
tissues. The toxicity and efficacy of this method in bone
sarcomas is studied in clinical trial setting [11,12].
Furthermore, the use of radiosensitizing drugs has
further improved the anti-tumor efficacy of radiotherapy
[3,5,8,13,14]. Conventional chemotherapy has been
shown to enhance the effect of radiotherapy in OS.
Gemcitabine (with or without Docetaxel) and Ifosfamide
have been shown to be potent radiosensitizers [3,15].
Also, the use of 153-Samarium can enhance the anti-
tumor effect of external beam radiotherapy in axial OS
[3,5,9,13]. Thus, chemotherapeutic agents may be used
as radiosensitizers in OS patients. Moreover, small
molecule inhibitor drugs may serve as additional radio-
sensitizers [13,16].
Radiotherapy, like many other cancer treatments,
induces damage to the DNA. Prolonged activation of
cell cycle checkpoints (arrest) is one effective method
exploited by cancer cells to repair DNA and thus evade
apoptosis after DNA-damaging treatments [16-20].
When cells progress through the cell cycle despite the
presence of DNA damage, as a result, they undergo a
mitosis specific cell death programme called mitotic cat-
astrophe [16-18,20-23]. Cancer cells often lack a func-
tional G0/1 cell cycle checkpoint and therefore rely
mainly on the G2 cell cycle arrest to gain time for DNA
repair [20,23-27]. Therefore, one strategy to sensitize OS
cells to DNA damaging treatments is to exploit their
vulnerability in defective cell cycle regulation and pre-
vent them from repairing the damaged DNA during G2
arrest. WEE1 kinase plays a dominant role in the sensi-
tivity of cancer cells to DNA damage by inhibitory phos-
phorylation of Cyclin-Dependent-Kinase 1 (CDC2),
thereby preventing mitotic entry, which is illustrated in
Figure 1A,[16-20,27-33]. It has been shown that
PD0166285, a small molecule WEE1 kinase inhibitor,
can abrogate the G2 checkpoint in cancer cells, forcing
DNA-damaged cells into premature mitotic entry thus
inducing mitotic catastrophe and sensitizing the cells to
apoptosis. The anti-tumor activity of WEE1 inhibition in
combination with DNA damaging treatments has been
demonstrated in vitro as well as in vivo models for dif-
ferent malignancies [16,21,28,29]. These promising pre-
clinical results have led to the testing of a small
molecule WEE1-inhibitor in a phase I clinical trial [27].
The aim of our study is to investigate if irradiation in
combination with WEE1 inhibition could be used as a
new therapeutic strategy to improve local control in the
treatment of OS.
Methods
Cell culture, irradiation and compounds
Human osteosarcoma cell lines MG-63, U2OS and
SaOS-2 were kindly provided by Dr. C. Löwik (Leiden
University Medical Center, Leiden, the Netherlands), Dr.
S. Lens (Dutch Cancer Institute, Amsterdam, the Neth-
erlands) and Dr. F. van Valen (Westfalische Wilhelms-
Universität, Münster, Germany) respectively. Human
primary (short-term culture) osteoblasts (ORT-1,
Hum31 and Hum54) were obtained from healthy
patients undergoing total knee replacement after
informed consent. Cells were cultured in D-MEM
(Gibco, Invitrogen) supplemented with 10% fetal calf
serum (FCS) and 1mg/mL Penicillin-Streptomycin
(Gibco) at 37°C and 5% CO2 in a humidified incubator.
Cells were irradiated in a Gammacell® 220 Research
Irradiator (MDS Nordion) at doses varying from 2 to 10
Gray (Gy). The WEE1-inhibitor PD0166285 (Pfizer, Ann
Arbor, MI, USA) was diluted in PBS to the desired con-
centration of 0.5 μM.
Immunohistochemistry
Paraffin embedded tissue samples of primary OS and OS
lung metastases, obtained from excision specimens from
our institute, were deparafinized and rehydrated. Endo-
genous peroxidase was inhibited by 30 minutes incuba-
tion of the sections in 0.3% H2O2, diluted in methanol.
Antigens were retrieved by boiling in citrate buffer (pH
6) for 10 minutes, followed by successive rinses in phos-
phate-buffered saline (PBS) containing 0.5% Triton and
then in PBS only. Slides were incubated for 10 minutes
in 0.1 M glycine (diluted in PBS) and rinsed in PBS.
Slides were incubated with mouse-anti-WEE1 (Santa-
Cruz) O/N at 4°C. Visualisation was performed using
the Power Vision+ Poly-HRP IHC Kit (Immunologic)
and tissue staining was performed with DAB chromogen
solution. Slides were counterstained with hematoxylin,
dehydrated and mounted. Placenta tissue served as posi-
tive control, prostate tissue served as negative control
(not shown). Images were acquired at 20x objective.
Western Blot
Basic expression levels of WEE1 and phosphorylated
CDC2 in human OS cell lines and human primary
osteoblasts were assessed by Western blot. Cells were
lysed in phospho-lysis buffer containing Protease and
Phosphatase Inhibitor Cocktails (Sigma). Proteins were
quantified with the BCA protein Assay Kit (Pierce). A
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total of 40 μg protein was separated on a SDS-PAGE gel
and transferred to a PVDF membrane, followed by incu-
bation with the primary antibodies: mouse anti-WEE1
(SantaCruz), mouse anti-b-actin (SantaCruz) and rabbit
anti-CDC2-pY15 (Abcam) and subsequently incubated
with secondary goat-anti-mouse and goat-anti-rabbit
immunoglobulins (DAKO). Protein detection and visua-
lization was performed using ECL+ Western Blotting
Detection Reagents (Pierce).
Inhibition of WEE1 kinase activity and concomitant
phosphorylation of CDC2 by the WEE1-inhibitor
PD0166285 was also analyzed by Western blot analysis.
Cells were plated and irradiated at a dose of 4 Gy in the
presence or absence of 0.5 μM PD0166285. After 4 h
treatment with 0.5 μM PD0166285, cells were lysed in
phospho-lysis buffer, followed by Western blot analysis
as described above.
Cell Viability and apoptosis assay
For cell viability analysis, OS cells and primary osteo-
blasts were plated in 96-well format and irradiated at
doses of 2, 3, 4, 6, 8 and 10 Gy. Cells were incubated
with 0.5 μM PD0166285 or PBS directly post-irradiation.
At 4 days (OS) and 9 days (osteoblasts) after treatment
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Figure 1 WEE1 kinase regulates the onset of mitosis and is expressed in human OS. (A) The Cyclin-B/CDC2 complex is considered the
master switch for the G2/M transition and CDC2 is designated the general controller in the onset of mitosis. Inhibition of the Cyclin-B/CDC2
complex prevents mitotic entry. CDC2 activation is essential for G2/M transition and thus progression through the cell cycle and is regulated on
multiple levels. Inhibitory phosphorylation of CDC2 is achieved by WEE1 and prevents proper association with Cyclin-B. Consequently, Cyclin-B
and CDC2 cannot form a complex and the complex cannot be activated. This induces a G2 arrest and prevents the cell cycle to progress until
DNA repair is completed. Dephosphorylation of CDC2 by the phosphatase CDC25C activates the Cyclin-B/CDC2 complex, allowing cell cycle
progression. The activation status of the Cyclin-B/CDC2 complex is dependent on the balance between WEE1 kinase and CDC25C phosphatase
activity, in which WEE1 kinase is the rate limiting, dominant molecule. (B) WEE1 mRNA expression is significantly higher in the OS samples when
compared to the normal tissue samples (ANOVA: p < 0.0001). (C) Panel C shows immunohistochemical staining of sections of primary OS
(extremity: II, III and axial: I, V) and OS lung metastasis (IVa,b). The brown nuclear staining indicates WEE1 expression in OS tumor tissue. (D)
Western blot analysis of the effect of PD0166285 on WEE1 function. Irradiated (IR) cells show increased expression levels of CDC2-pY15 (CDC2-p)
compared to untreated cells. After subsequent treatment with WEE1-inhibitor PD0166285 (WEE1-i), CDC2-pY15 expression levels are diminished,
indicative of inhibition of WEE1 kinase activity. (E) Baseline expression levels of phosphorylated CDC (CDC2-p), the most important molecular
target of WEE1 kinase, are distinctly lower in human primary osteoblasts compared to human OS cells.
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cell viability was assessed using the CellTiter-Blue Cell
Viability Assay (Promega) according to the manufac-
turer’s instructions.
To analyse apoptosis, OS cells were plated in white
opaque 96-well plates and treated with 4 Gy irradiation
or with combination treatment of 4 Gy and 0.5 μM
PD0166285. At 6 h and 24h post-irradiation, caspase
activity was measured using the Caspase-Glo 3/7 assay
(Promega) according to the manufacturer’s instructions.
Fluorescence and luminescence read-out was per-
formed using a Tecan Infinite F200 Microplate Reader
(Tecan Trading AG, Switzerland). Results were analysed
using GraphPad Prism® Version 5.01 (GraphPad Soft-
ware, Inc. San Diego, CA, USA).
Flow cytometry
Cell cycle distribution and the percentage of mitotic
cells were analysed using flow cytometry. Cells were pla-
ted and treated with 4 Gy irradiation, 0.5 μM
PD0166285 or combination treatment. At 20 h after
treatment cells were trypsinized, washed in PBS contain-
ing 1% FCS and fixed in 70% ice-cold ethanol for 24 h.
After fixation, cells were washed with PBS containing
1% FCS and incubated with rat-anti-phospho-histone
H3 (PHH3) antibody (BD Pharmingen) in PBS contain-
ing 1% BSA for 2 h at room temperature, followed by
secondary antibody incubation with rabbit-anti-rat/FITC
immunoglobulins (DAKO) in PBS containing 1% BSA
for 30 minutes at room temperature in the dark. Cells
were washed once and DNA was stained with 50 μg/mL
propidium iodide (PI) solution in the presence of 250
μg/mL RNAseA (Sigma). The DNA content and the
percentage of PHH3 positive cells were measured using
a FacsCalibur Flow Cytometer and the Cell Quest Pro
programme (Becton Dickinson) and results were subse-
quently analysed using ModFitLT software (Verity Soft-
ware House, Topsham, ME, USA).
Immunofluorescent Staining
OS cells were seeded on glass coverslips in 24-well
plates and treated with 4 Gy irradiation or with combi-
nation treatment of 4 Gy and 0.5 μM PD0166285. At 1
h and 24 h post-irradiation cells were fixed in 2% paraf-
ormaldehyde. Prior to staining, the cells were rinsed in
PBS and permeabilized in PBS containing 0.1% Trition
X-100 for 30 minutes at room temperature and blocked
in PBS containing 5% FCS. Slips were incubated with
mouse-anti-g-histone-H2AX (Millipore) in PBS contain-
ing 5% FCS O/N at 4°C, followed by secondary antibody
incubation rabbit-anti-mouse/FITC immunoglobulins
(DAKO) in PBS containing 5% FCS for 30 minutes at
room temperature in the dark. Slips were rinsed in PBS
thrice and nuclei were stained with DAPI (1:10 000) in
PBS at room temperature in the dark, followed by
successive rinses in PBS and sterile water. The slips
were then mounted on glass slides, fixed with Mowiol
and analyzed with a Carl Zeiss Axioskop 20 microscope
at 100x objective.
Results
To investigate whether WEE1 could be a suitable drug
target in human OS we first explored its expression
levels. From publicly available gene expression data in
the GEO Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo: GSE14827), we analyzed WEE1 expression in
27 OS samples and 504 various normal tissue samples
using the software programme R2 [34]. We determined
that WEE1 kinase is overexpressed in OS compared to
various normal tissues, as shown in Figure 1B. When
comparing the mRNA expression level of WEE1 in OS
samples to the normal various tissue samples, one-way
analysis-of-variance (ANOVA) shows that WEE1 expres-
sion is significantly higher in the OS samples (p <
0.0001). In addition, we determined WEE1 protein
expression in human OS tissue sections by immunohis-
tochemical staining. Five out of 6 tested tumors had
positive nuclear WEE1 staining (Figure 1C). The nuclear
localization of the protein is in concordance with its
role in cell cycle regulation. These data indicate that
WEE1 is indeed expressed by OS and could thus serve
as a potential drug target.
Next, we assessed whether PD0166285 can inhibit
WEE1 kinase function by determining phosphorylation
of its target CDC2 (resulting in CDC2-pY15) using Wes-
tern blot analysis. Irradiated cells showed a moderate
increase in WEE1 expression and a more profound
increase in expression of CDC2 -pY15 compared to
untreated cells (Figure 1D). This supports the notion
that WEE1 kinase plays a role in the response to DNA
damage by phosphorylation of CDC2. Subsequent treat-
ment with PD0166285 diminished the expression of
CDC2 -pY15 after irradiation. This shows that
PD0166285 effectively inhibits WEE1 activity and thus
reduces the inhibitory phosphorylation of CDC2 in OS
cells.
To analyse how baseline WEE1 and CDC2- pY15 levels
in OS cells compare to normal cells, we included a wes-
tern blot analysis. Figure 1E shows that CDC2- pY15
levels in human primary osteoblasts are negligible in
comparison to the OS cell lines. WEE1 expression in
the osteoblasts could not be visualised.
To investigate the effects of WEE1 inhibition on OS
cell survival after g-irradiation-induced DNA damage,
we compared cell viability in irradiated cells in the pre-
sence or absence of the WEE1-inhibitor PD0166285.
Figure 2A shows that WEE1 inhibition using
PD0166285 at a non-toxic dose (0.5 μM) increased cell
death after 2 to 6 Gy g-irradiation in the OS cell lines
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MG-63, U2OS and SaOS-2 (p < 0.01), whereas treat-
ment with 0.5 μM WEE1-inhibitor alone showed no
effect on cell viability (data not shown). To ascertain
that WEE1 inhibition does not radiosensitize normal
cells, we compared cell viability of human primary
osteoblasts to osteosarcoma cell lines after 4 Gy irradia-
tion, in the presence or absence of 0.5 μM PD0166285.
Figure 2B shows that in the osteosarcoma cell lines
there is a clear sensitization to irradiation treatment,
with approximately a 2-fold reduction in cell viability
after combination treatment. In contrast, in the human
osteoblasts no such effects were seen. There is a minor
decrease in cell viability due to the irradiation treatment,
but WEE1 inhibition does not enhance cell death. The
results were consistent for all three tested human pri-
mary osteoblasts. From this we conclude that OS cells
are indeed sensitized to irradiation whereas normal cells
are not.
To investigate if the sensitizing effect of WEE1 inhibi-
tion in OS could be explained by mitotic catastrophe,
we looked into three aspects of this phenomenon. We
performed FACS cell cycle analysis of cells treated with
4 Gy g-irradiation, 0.5 μM PD0166285, and combination
treatment. Cells were stained with PI to analyse DNA
content and with PHH3 to distinguish the fraction of
mitotic cells from the cells in G2/M phase. Treatment
with the WEE1-inhibitor alone did not alter the cell
cycle distribution (Figure 3A). Irradiation of the cells
resulted in arrest in the G2/M phase, indicated by an
accumulation of cells with 4N DNA content, but a
stable percentage of mitotic cells. However, upon treat-
ment of the irradiated cells with the WEE1-inhibitor, a
clear abrogation of G2 arrest was observed. Additionally,
there was a 2 to 4-fold increase in the percentage of
mitotic cells.
To assess the extent of g-irradiation-induced double
strand DNA breaks (DSBs), we visualized the number of
ionizing radiation induced foci (IRIF) with DSB marker
g-H2AX at 1 h and 24 h after irradiation, in cells irra-
diated at a dose of 4 Gy in the presence or absence of
0.5 μM PD0166285. Figure 3B shows that DNA damage
is visible at 1 h after irradiation. In the irradiated cells,
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Figure 2 WEE1-inhibition sensitizes OS cells to g-irradiation but not normal cells. (A) Indicated are dose response curves of irradiated cells
(squares) and cells treated with IR + WEE1-inhibitor (triangles). The curves represent three experiments, performed in triplicate; error bars
indicate standard deviation (SD). The sensitizing effect of WEE1 inhibition is significant in all three OS cell lines (student’s t-test: p < 0.01) (B)
Analysis of cell viability of human OS cell lines and human primary osteoblasts treated with 4 Gray (Gy) IR in the presence or absence of WEE1-
inhibitor. Bars represent experiments performed in triplicate; error bars indicate SD. The OS cell lines MG-63, U2OS and SaOS-2 show a 2-fold
decrease in cell viability when treated with combination therapy, whereas human primary osteoblasts ORT-1, Hum31 and Hum54 do not show
sensitization to radiotherapy in the presence of the WEE1-inhibitor.
PosthumaDeBoer et al. BMC Cancer 2011, 11:156
http://www.biomedcentral.com/1471-2407/11/156
Page 5 of 8
only a few residual foci are detectable after 24h com-
pared to the 1h time point, indicating that DNA repair
has occurred or is still ongoing. The shape of the nuclei
is regular and there are no clear signs of apoptosis. In
contrast, the cells treated with irradiation in combina-
tion with WEE1-inhibitor show extensive remaining
DNA damage after 24 h with irregularity and fragmenta-
tion of nuclei indicative of nuclear envelope disassembly
and apoptosis. From this we derive that in WEE1 inhib-
ited cells DNA repair is not effectively realized.
To verify that cell death occurs as a result of apoptosis
we analysed caspase activation in irradiated cells in the
presence or absence of WEE1-inhibitor (Figure 3C). At
6 h post-irradiation there is a mild caspase activation in
cells treated with irradiation alone or with combination
treatment. However, at 24 h post-irradiation there is a
distinct difference in caspase activation between irra-
diated cells (4 to 6-fold) and cells treated with the com-
bination of irradiation and WEE1-inhibitor (11 to 22-
fold) (p < 0.01 for all three cell lines). Taken together,
this implies that cells treated with the WEE1-inhibitor
are forced to proceed through the G2 cell cycle
checkpoint into mitotic entry despite the presence of
DNA damage and are therefore sensitized to g-irradia-
tion-induced apoptosis.
Discussion
In this work, we explore the possibility to use WEE1
inhibition as a new therapeutic strategy in OS. The use
of WEE1-inhibitor PD0166285 to obtain radiosensitiza-
tion in various malignancies has been reported pre-
viously [18,21,28,29]. The radiosensitization effect is
described to be particularly effective in, if not limited to,
p53 deficient malignancies [18,28]. Interestingly, we
have found that our tested cell lines can all be sensitized
to irradiation, regardless of their p53 status (wt in
U2OS, mutated in MG-63 and null in SaOS-2). This, we
ascribe to the idea that a defective G1 checkpoint is not
necessarily caused by p53 mutations alone but rather a
disruption in the p53 pathway, which can be caused by
other aberrations within this pathway. We show that
after irradiation, OS cells accumulate in a predominant
G2 arrest, the abrogation of which effectively leads to
mitotic catastrophe.
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the percentages of mitotic cells remained unaltered. After subsequent treatment with WEE1-inhibitor, the G2 arrest is completely abrogated; the
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combination treatment for all cell lines (student’s t-test: p < 0.01).
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As was reported previously [21,27], our results con-
firm that normal cells remain unaffected by WEE1 inhi-
bition after irradiation. We tested human primary
osteoblasts for their response to irradiation in the pre-
sence or absence of WEE1-inhibitor. While there was a
minor effect of irradiation on cell viability, no radiosen-
sitization by PD0166285 was observed. This is likely
explained by a functional G1 checkpoint with concurrent
wild type p53 expression. This indicates that WEE1
inhibition is a safe strategy to apply in OS patients
because the radiosensitization would be cancer cell
specific.
Apart from being a regulator of mitotic entry, WEE1
has been described to also affect other important cellu-
lar processes, such as regulation of mitotic spindle for-
mation, positioning and integrity, microtubule
stabilization and heat shock protein 90 (Hsp90) phos-
phorylation [29,35,36]. In this paper, we have not exam-
ined these phenomena, but it could be that the
disruption of one of these processes contributes to the
observed phenotype. It may be interesting to study these
additional effects in the future.
Timing of combination therapy is important to obtain
optimal treatment efficacy. It was reported that CDC2 is
transiently phosphorylated to induce an arrest at the
G2/M checkpoint for 12 h after irradiation treatment
and that DNA damage could be repaired in 12-24 h
after irradiation [19]. Our results support this; in irra-
diated cells, we observed only few remaining foci of
DNA damage after 24h, whereas cells treated with irra-
diation and WEE1-inhibitor had many residual foci after
24h, indicating that they were unable to perform DNA
repair. This suggests that DNA damaged cells are espe-
cially susceptible to WEE1-inhibitor in the first 12h
after induction of DNA damage. In our experimental
set-up, the cells were treated with WEE1-inhibitor
directly after irradiation and show a good sensitization.
This suggests that cells do not have to be arrested in
G2/M phase to be susceptible to WEE1 inhibition, but
rather that the inability to activate (or maintain) the G2
checkpoint in the presence of DNA damage leads to
sensitization. In in vivo testing of WEE1-inhibitors, dif-
ferent approaches have been applied. Mir et al. [21]
administered WEE1-inhibitor at 5 consecutive days
around the irradiation dose, whereas Hirai et al. [18]
first administered DNA damaging agents, followed by
WEE1-inhibitor after a 24 hour interval. Both groups
showed enhanced anti-tumor efficacy. What will be the
most optimal schedule for radiotherapy combined with
WEE1 inhibition in OS remains to be tested in vivo.
Conclusion
Radiotherapy is a controversial topic in the treatment of
OS. Its efficacy is limited in this cancer and therefore it
is not widely applied. Novel small molecules, in particu-
lar WEE1-inhibitor drugs may serve as radiosensitizers
in OS. WEE1 kinase is expressed in OS and plays a cri-
tical role in DNA repair by maintaining the G2 cell
cycle arrest through inhibitory phosphorylation of
CDC2. Our results show that the WEE1-inhibitor
PD0166285 can abrogate the DNA damage induced G2/
M cell cycle arrest in OS cells, forcing the cells into
mitotic catastrophe and thus causing radiosensitization.
WEE1 could therefore be a strategic, cancer cell specific
drug target and its inhibition could be an effective strat-
egy to enhance the efficacy of radiotherapy in OS.
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